Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2002 Oct 15;367(Pt 2):451–458. doi: 10.1042/BJ20020696

Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.

Anna C Cunningham 1, Karen A Hasty 1, Jan J Enghild 1, Alan E Mast 1
PMCID: PMC1222898  PMID: 12117418

Abstract

Vascular injury results in the activation of coagulation and the release of proteolytic enzymes from neutrophils and connective- tissue cells. High concentrations of these inflammatory proteinases may destroy blood coagulation proteins, contributing to coagulation and bleeding disorders associated with severe inflammation. Matrix metalloproteinase-8 (MMP-8) is released from neutrophils at sites of inflammation and vascular disease. We have investigated the effect of MMP-8 degradation on the anticoagulant function of tissue factor pathway inhibitor (TFPI) as a potential pathological mechanism contributing to coagulation disorders. MMP-8 cleaves TFPI following Ser(174) within the connecting region between the second and third Kunitz domains ( k (cat)/ K (m) approximately 75 M(-1).s(-1)) as well as following Lys(20) within the NH(2)-terminal region. MMP-8 cleavage of TFPI decreases the anticoagulant activity of TFPI in factor Xa initiated clotting assays as well as the ability of TFPI to inhibit factor Xa in amidolytic assays. Yet, MMP-8 cleavage does not alter the ability of TFPI to inhibit trypsin. Since the inhibition of both factor Xa and trypsin is mediated by binding to the second Kunitz domain, these results suggest that regions of TFPI other than the second Kunitz domain may directly interact with factor Xa. (125)I-factor Xa ligand blots of TFPI fragments generated following MMP-8 degradation were used for probing binding interactions between factor Xa and regions of TFPI, other than the second Kunitz domain. In experiments performed under reducing conditions that disrupt the Kunitz domain structure, (125)I-factor Xa binds to the C-terminal fragment of MMP-8-degraded TFPI. This fragment contains portions of TFPI distal to Ser(174), which include the third Kunitz domain and the basic C-terminal region. An altered form of TFPI lacking the third Kunitz domain, but containing the C-terminal region, was used to demonstrate that the C-terminal region directly interacts with factor Xa.

Full Text

The Full Text of this article is available as a PDF (205.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ardissino D., Merlini P. A., Ariëns R., Coppola R., Bramucci E., Mannucci P. M. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet. 1997 Mar 15;349(9054):769–771. doi: 10.1016/S0140-6736(96)11189-2. [DOI] [PubMed] [Google Scholar]
  2. Baugh R. J., Broze G. J., Jr, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem. 1998 Feb 20;273(8):4378–4386. doi: 10.1074/jbc.273.8.4378. [DOI] [PubMed] [Google Scholar]
  3. Belaaouaj A. A., Li A., Wun T. C., Welgus H. G., Shapiro S. D. Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J Biol Chem. 2000 Sep 1;275(35):27123–27128. doi: 10.1074/jbc.M004218200. [DOI] [PubMed] [Google Scholar]
  4. Bickett D. M., Green M. D., Berman J., Dezube M., Howe A. S., Brown P. J., Roth J. T., McGeehan G. M. A high throughput fluorogenic substrate for interstitial collagenase (MMP-1) and gelatinase (MMP-9). Anal Biochem. 1993 Jul;212(1):58–64. doi: 10.1006/abio.1993.1291. [DOI] [PubMed] [Google Scholar]
  5. Broze G. J., Jr, Girard T. J., Novotny W. F. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry. 1990 Aug 21;29(33):7539–7546. doi: 10.1021/bi00485a001. [DOI] [PubMed] [Google Scholar]
  6. Drew A. F., Davenport P., Apostolopoulos J., Tipping P. G. Tissue factor pathway inhibitor expression in atherosclerosis. Lab Invest. 1997 Oct;77(4):291–298. [PubMed] [Google Scholar]
  7. Girard T. J., Warren L. A., Novotny W. F., Likert K. M., Brown S. G., Miletich J. P., Broze G. J., Jr Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature. 1989 Apr 6;338(6215):518–520. doi: 10.1038/338518a0. [DOI] [PubMed] [Google Scholar]
  8. Hanemaaijer R., Sorsa T., Konttinen Y. T., Ding Y., Sutinen M., Visser H., van Hinsbergh V. W., Helaakoski T., Kainulainen T., Rönkä H. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J Biol Chem. 1997 Dec 12;272(50):31504–31509. doi: 10.1074/jbc.272.50.31504. [DOI] [PubMed] [Google Scholar]
  9. Hasty K. A., Hibbs M. S., Kang A. H., Mainardi C. L. Secreted forms of human neutrophil collagenase. J Biol Chem. 1986 Apr 25;261(12):5645–5650. [PubMed] [Google Scholar]
  10. Hasty K. A., Jeffrey J. J., Hibbs M. S., Welgus H. G. The collagen substrate specificity of human neutrophil collagenase. J Biol Chem. 1987 Jul 25;262(21):10048–10052. [PubMed] [Google Scholar]
  11. Henderson P. J. A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors. Biochem J. 1972 Apr;127(2):321–333. doi: 10.1042/bj1270321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Herman M. P., Sukhova G. K., Kisiel W., Foster D., Kehry M. R., Libby P., Schönbeck U. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest. 2001 May;107(9):1117–1126. doi: 10.1172/JCI10403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Herman M. P., Sukhova G. K., Libby P., Gerdes N., Tang N., Horton D. B., Kilbride M., Breitbart R. E., Chun M., Schönbeck U. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation. 2001 Oct 16;104(16):1899–1904. doi: 10.1161/hc4101.097419. [DOI] [PubMed] [Google Scholar]
  14. Higuchi D. A., Wun T. C., Likert K. M., Broze G. J., Jr The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood. 1992 Apr 1;79(7):1712–1719. [PubMed] [Google Scholar]
  15. Hirose T., Patterson C., Pourmotabbed T., Mainardi C. L., Hasty K. A. Structure-function relationship of human neutrophil collagenase: identification of regions responsible for substrate specificity and general proteinase activity. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2569–2573. doi: 10.1073/pnas.90.7.2569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Huang Z. F., Higuchi D., Lasky N., Broze G. J., Jr Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood. 1997 Aug 1;90(3):944–951. [PubMed] [Google Scholar]
  17. Kaikita K., Takeya M., Ogawa H., Suefuji H., Yasue H., Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol. 1999 Jun;188(2):180–188. doi: 10.1002/(SICI)1096-9896(199906)188:2<180::AID-PATH338>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  18. Li A., Wun T. C. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity. Thromb Haemost. 1998 Sep;80(3):423–427. [PubMed] [Google Scholar]
  19. Liu Z., Zhou X., Shapiro S. D., Shipley J. M., Twining S. S., Diaz L. A., Senior R. M., Werb Z. The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell. 2000 Sep 1;102(5):647–655. doi: 10.1016/s0092-8674(00)00087-8. [DOI] [PubMed] [Google Scholar]
  20. Lockett J. Marcus, Mast Alan E. Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor. Biochemistry. 2002 Apr 16;41(15):4989–4997. doi: 10.1021/bi016058n. [DOI] [PubMed] [Google Scholar]
  21. Loebermann H., Tokuoka R., Deisenhofer J., Huber R. Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol. 1984 Aug 15;177(3):531–557. [PubMed] [Google Scholar]
  22. Mast A. E., Enghild J. J., Nagase H., Suzuki K., Pizzo S. V., Salvesen G. Kinetics and physiologic relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kDa gelatinase/type IV collagenase), and -3 (stromelysin). J Biol Chem. 1991 Aug 25;266(24):15810–15816. [PubMed] [Google Scholar]
  23. Maynard J. R., Dreyer B. E., Stemerman M. B., Pitlick F. A. Tissue-factor coagulant activity of cultured human endothelial and smooth muscle cells and fibroblasts. Blood. 1977 Sep;50(3):387–396. [PubMed] [Google Scholar]
  24. Nemerson Y., Bach R. Tissue factor revisited. Prog Hemost Thromb. 1982;6:237–261. [PubMed] [Google Scholar]
  25. Nwomeh B. C., Liang H. X., Cohen I. K., Yager D. R. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers. J Surg Res. 1999 Feb;81(2):189–195. doi: 10.1006/jsre.1998.5495. [DOI] [PubMed] [Google Scholar]
  26. Ohkura N., Enjyoji K., Kamikubo Y., Kato H. A novel degradation pathway of tissue factor pathway inhibitor: incorporation into fibrin clot and degradation by thrombin. Blood. 1997 Sep 1;90(5):1883–1892. [PubMed] [Google Scholar]
  27. Petersen L. C., Bjørn S. E., Nordfang O. Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemost. 1992 May 4;67(5):537–541. [PubMed] [Google Scholar]
  28. Petersen L. C., Bjørn S. E., Olsen O. H., Nordfang O., Norris F., Norris K. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor. Eur J Biochem. 1996 Jan 15;235(1-2):310–316. doi: 10.1111/j.1432-1033.1996.0310f.x. [DOI] [PubMed] [Google Scholar]
  29. Sanchez-Lopez R., Nicholson R., Gesnel M. C., Matrisian L. M., Breathnach R. Structure-function relationships in the collagenase family member transin. J Biol Chem. 1988 Aug 25;263(24):11892–11899. [PubMed] [Google Scholar]
  30. Sukhova G. K., Schönbeck U., Rabkin E., Schoen F. J., Poole A. R., Billinghurst R. C., Libby P. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 1999 May 18;99(19):2503–2509. doi: 10.1161/01.cir.99.19.2503. [DOI] [PubMed] [Google Scholar]
  31. Warshawsky I., Bu G., Mast A., Saffitz J. E., Broze G. J., Jr, Schwartz A. L. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest. 1995 Apr;95(4):1773–1781. doi: 10.1172/JCI117855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Weiss S. J., Peppin G., Ortiz X., Ragsdale C., Test S. T. Oxidative autoactivation of latent collagenase by human neutrophils. Science. 1985 Feb 15;227(4688):747–749. doi: 10.1126/science.2982211. [DOI] [PubMed] [Google Scholar]
  33. Wesselschmidt R., Likert K., Girard T., Wun T. C., Broze G. J., Jr Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood. 1992 Apr 15;79(8):2004–2010. [PubMed] [Google Scholar]
  34. Wesselschmidt R., Likert K., Huang Z., MacPhail L., Broze G. J., Jr Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis. 1993 Oct;4(5):661–669. [PubMed] [Google Scholar]
  35. Wilhelm S. M., Collier I. E., Marmer B. L., Eisen A. Z., Grant G. A., Goldberg G. I. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem. 1989 Oct 15;264(29):17213–17221. [PubMed] [Google Scholar]
  36. Wun T. C., Kretzmer K. K., Girard T. J., Miletich J. P., Broze G. J., Jr Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem. 1988 May 5;263(13):6001–6004. [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES